All In Biotech

Drug Trial Radar · NCT06600789

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 16, 2024

Primary completion

Mar 14, 2027

Study completion Mar 14, 2027

Sponsor

Lead sponsor
Carrick Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.

Conditions

  • Solid Malignancies

Interventions

  • CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg)Drug

    CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed. Different dosing schedules might be explored in cohorts (BID or intermitting dosing).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events will be assessed as per CTCAE v5.0.Time frame: From first dosing at Cycle 0 to until 30 days after the last dose at Cycle 6. Each cycle is 28 days
  2. Incidence and severity of treatment emergent Laboratory Abnormalities will be assessed as per CTCAE v5.0.Time frame: From first dosing at Cycle 0 to until 30 days after the last dose at Cycle 6. Each cycle is 28 days.
  3. Change from Baseline in Eastern Cooperative Oncology Group Cooperative Oncology Group (ECOG) Performance scale.Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  4. Systolic Blood Pressure as determined by blood pressure changes from baseline in systolic blood pressure (measured in mmHg)Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  5. Diastolic Blood Pressure as determined by blood pressure changes from baseline in diastolic blood pressure (measured in mmHg)Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  6. Heart Rate as determined by heart rate changes from baseline in beats per minuteTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  7. Body Temperature. as determined by body temperature changes from baseline in Celsius or FahrenheitTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days) End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  8. Respiratory Rate as determined by respiratory rate changes from baseline in breaths per minuteTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  9. Oxygen Saturation as determined by changes from baseline in %Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  10. Change from Baseline in 12-lead Electrocardiogram (ECG): Heart RateTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  11. Change from Baseline in 12-lead Electrocardiogram (ECG): PR intervalTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  12. Change from Baseline in 12-lead Electrocardiogram (ECG): QRS complexTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  13. Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervalsTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  14. Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula)Time frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
  15. Module 1 Part A additional primary outcome measures: Maximum tolerated dose (MTD) determinationTime frame: Up to 28 days after the first dose of CT7439

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Research site 03

    Dallas, Texas · Recruiting

  • Research site 01

    San Antonio, Texas · Recruiting

  • Research site 02

    Fairfax, Virginia · Recruiting

  • Research site 05

    Manchester, United Kingdom · Recruiting

  • Research site 04

    Oxford, United Kingdom · Recruiting

  • Research site 06

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.